Repurposing Itraconazole for the Treatment of Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2017 Sep 21

PMID 28927025

Citations 20

Authors

Rachel Pounds

Sarah Leonard

Christopher Dawson

Sean Kehoe

Affiliations

Soon will be listed here.

Abstract

The repurposing of drugs is becoming increasingly attractive as it avoids the lengthy process and cost implications associated with bringing a novel drug to market. Itraconazole is a broad-spectrum anti-fungal agent. An emerging body of , and clinical evidence have confirmed that it also possesses antineoplastic activities and has a synergistic action when combined with other chemotherapeutic agents. It acts via several mechanisms to prevent tumour growth, including inhibition of the Hedgehog pathway, prevention of angiogenesis, decreased endothelial cell proliferation, cell cycle arrest and induction of auto-phagocytosis. These allow itraconazole, either alone or in combination with other cytotoxic agents, to increase drug efficacy and overcome drug resistance. This study reviews the reported literature on the use of itraconazole in a variety of malignancies and highlights the recent insights into the critical pathways acted upon to prevent tumour growth.

Citing Articles

Itraconazole promotes melanoma cells apoptosis via inhibiting hedgehog signaling pathway-mediated autophagy.

Jin S, Liu X, Cai L, Yan J, Li L, Dong H Front Pharmacol. 2025; 16:1545243.

PMID: 39917616 PMC: 11798931. DOI: 10.3389/fphar.2025.1545243.

Cancer Metabolism as a Therapeutic Target and Review of Interventions.

Halma M, Tuszynski J, Marik P Nutrients. 2023; 15(19).

PMID: 37836529 PMC: 10574675. DOI: 10.3390/nu15194245.

Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options.

Borella F, Fucina S, Mangherini L, Cosma S, Carosso A, Cusato J Biomedicines. 2023; 11(8).

PMID: 37626654 PMC: 10452581. DOI: 10.3390/biomedicines11082157.

Repurposing antifungal drugs for cancer therapy.

Weng N, Zhang Z, Tan Y, Zhang X, Wei X, Zhu Q J Adv Res. 2022; 48:259-273.

PMID: 36067975 PMC: 10248799. DOI: 10.1016/j.jare.2022.08.018.

Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management.

Jin P, Jiang J, Zhou L, Huang Z, Nice E, Huang C J Hematol Oncol. 2022; 15(1):97.

PMID: 35851420 PMC: 9290242. DOI: 10.1186/s13045-022-01313-4.

References

Vreugdenhil G, van Dijke B, Donnelly J, Novakova I, Raemaekers J, Koster M . Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma. 1993; 11(5-6):353-8. DOI: 10.3109/10428199309067926. View

Ruiz i Altaba A, Sanchez P, Dahmane N . Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer. 2002; 2(5):361-72. DOI: 10.1038/nrc796. View

Kim J, Aftab B, Tang J, Kim D, Lee A, Rezaee M . Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013; 23(1):23-34. PMC: 3548977. DOI: 10.1016/j.ccr.2012.11.017. View

Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K . Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 2000; 22(12):1355-9. DOI: 10.1248/bpb.22.1355. View

Liu M, Mo Q, Wei C, Qin Q, Huang Z, He J . Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis. Oncol Lett. 2013; 5(3):983-991. PMC: 3576281. DOI: 10.3892/ol.2012.1093. View

Antonarakis E, Heath E, Smith D, Rathkopf D, Blackford A, Danila D . Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist. 2013; 18(2):163-73. PMC: 3579600. DOI: 10.1634/theoncologist.2012-314. View

Itamochi H, Kigawa J, Sultana H, Iba T, Akeshima R, Kamazawa S . Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res. 2002; 93(6):723-8. PMC: 5927055. DOI: 10.1111/j.1349-7006.2002.tb01312.x. View

Kajiyama H, Shibata K, Mizuno M, Yamamoto E, Fujiwara S, Umezu T . Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma. Int J Gynecol Cancer. 2012; 22(5):801-6. DOI: 10.1097/IGC.0b013e3182540145. View

Tannock I, de Wit R, Berry W, Horti J, Pluzanska A, Chi K . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15):1502-12. DOI: 10.1056/NEJMoa040720. View

10.

Tsubamoto H, Sonoda T, Ikuta S, Tani S, Inoue K, Yamanaka N . Impact of Itraconazole After First-line Chemotherapy on Survival of Patients with Metastatic Biliary Tract Cancer. Anticancer Res. 2015; 35(9):4923-7. View

11.

Gupta A, Unadkat J, Mao Q . Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J Pharm Sci. 2007; 96(12):3226-35. DOI: 10.1002/jps.20963. View

12.

Wang Y, Yao Y, Liu H, Ma X, Lv T, Yuan D . Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice. Transl Lung Cancer Res. 2015; 4(1):27-35. PMC: 4367708. DOI: 10.3978/j.issn.2218-6751.2014.11.03. View

13.

Lockhart N, Waddell J, Schrock N . Itraconazole therapy in a pancreatic adenocarcinoma patient: A case report. J Oncol Pharm Pract. 2015; 22(3):528-32. DOI: 10.1177/1078155215572931. View

14.

Sarkar S, Goldgar S, Byler S, Rosenthal S, Heerboth S . Demethylation and re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy. Epigenomics. 2013; 5(1):87-94. DOI: 10.2217/epi.12.68. View

15.

Kurosawa M, Okabe M, Hara N, Kawamura K, Suzuki S, Sakurada K . Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells. Ann Hematol. 1996; 72(1):17-21. DOI: 10.1007/BF00663011. View

16.

Aftab B, Dobromilskaya I, Liu J, Rudin C . Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res. 2011; 71(21):6764-72. PMC: 3206167. DOI: 10.1158/0008-5472.CAN-11-0691. View

17.

Suzman D, Antonarakis E . High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer. Clin Genitourin Cancer. 2013; 12(2):e51-3. PMC: 3959234. DOI: 10.1016/j.clgc.2013.11.015. View

18.

Ally M, Ransohoff K, Sarin K, Atwood S, Rezaee M, Bailey-Healy I . Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma. JAMA Dermatol. 2016; 152(4):452-6. PMC: 4833646. DOI: 10.1001/jamadermatol.2015.5473. View

19.

Wahid M, Jawed A, Mandal R, Dar S, Khan S, Akhter N . Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas. Crit Rev Oncol Hematol. 2015; 98:235-41. DOI: 10.1016/j.critrevonc.2015.11.006. View

20.

Vreugdenhil G, Raemaekers J, van Dijke B, De Pauw B . Itraconazole and multidrug resistance: possible effects on remission rate and disease-free survival in acute leukemia. Ann Hematol. 1993; 67(3):107-9. DOI: 10.1007/BF01701730. View